Category: Pharmaceutical Industry
-
Pharma giant Takeda ordered to pay over $884 million in damages in Amitiza class action suit: patent litigation settlement was anticompetitive, jury finds
Takeda has said it already plans to “vigorously” appeal the decision, which found its 2014 deal with competitor Par Pharmaceutical to drop its challenge to its AMITIZA patents and delay its generic entry by seven years, anticompetitive.
-
Actelion falls foul of disclosure-dedication rule, prosecution estoppel in Federal Circuit challenge to Mylan’s hypertension generic
The Federal Circuit agreed that there was neither literal infringement, nor infringement under the doctrine of equivalents.
-
Federal Circuit analysis would create “substantial disincentive” to generic entry, USDOJ tells Supreme Court in Hikma v. Amarin
The key arguments centred on whether it was plausible that Hikma’s marketing amounted to inducement to infringe.
-
Merz wins UPC appeal as CoA overturns Paris LD denial and grants PI against Viatris generic in France
The UPC CoA has reversed the Paris LDâs refusal of interim relief and granted Merz a preliminary injunction against Viatris SantĂ©âs fampridine generic in France.
-
CureVac sues Moderna in Delaware over Spikevax patents, seeking treble damages but no injunction
CureVac sues Moderna for treble damages but not an injunction over 10 patents related to Spikevax. The case adds to broader post-COVID mRNA patent battles.
-
ECJ Advocate General says excipient label is binding for SPC purposes: Halozyme v. Czech IPO
AG Emiliou says a substance in a MA that is called an excipient may not be considered an active ingredient for SPC purposes, which would invalidate grants in eight EU member states.
-
Another semaglutide generic enters India as Novo Nordisk patent expires, no injunction issuesÂ
The Delhi High Court has issued a ruling allowing a generic version of semaglutide to be sold without an injunction and indicating a cautious approach to late-stage enforcement, favoring restricted entry over exclusion, by basing it around a contested claim limitation.
-
Colombia pushes for compulsory licensing of U.S. pharma companyâs patents
Colombiaâs Health Minister has revived a previous administrationâs investigation into four of U.S. pharma company Gileadâs patents at the core of Hepatitis-C treatment, issuing a public interest declaration to make the licensing of such patents compulsory.
-
Novo Nordisk settles U.S. semaglutide patent infringement dispute, but denied Indian interim injunction again
While Novo Nordisk has struck an agreement with U.S. telehealth platform Hims & Hers to sell Ozempic and Wegovy, the Delhi High Court has once again denied its request for an interim injunction against Dr. Reddyâs Laboratories to block its sales of semaglutide products after its patent expires in 10 days.
-
An interview with bioMĂ©rieux IP head Dr. James Robertson
James Robertson, the in vitro diagnostics companyâs global head of IP, talked to ip fray about its activities in the Unified Patent Court and some of the successes and hurdles he has experienced since moving from pharma into diagnostics IP management.Â